In clinical studies, Zaffaroni et al (2002) showed that high levels of survivin protein are associated with resistance to regimens containing the microtubule-targeting agent paclitaxel, but are unrelated to cisplatin responsiveness in advanced ovarian cancer. Here, BIRC5 is linked to ovarian carcinoma.